Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis

Risankizumab, a humanized monoclonal antibody that targets interleukin‐23 p19 subunit, was developed for the treatment of psoriasis. This work characterizes risankizumab pharmacokinetics in Japanese and Chinese healthy subjects compared with white healthy subjects and in Japanese patients with moder...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatri, Amit, Eckert, Doerthe, Oberoi, Rajneet, Suleiman, Ahmed, Pang, Yinuo, Cheng, Ling, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852105/
https://www.ncbi.nlm.nih.gov/pubmed/31257614
http://dx.doi.org/10.1002/jcph.1473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852105/
https://www.ncbi.nlm.nih.gov/pubmed/31257614
http://dx.doi.org/10.1002/jcph.1473

Ejemplares similares